When does the patent on Eliquis (apixaban) expire?
Eliquis (apixaban) is protected by multiple patents that cover different aspects of the drug (the active ingredient, formulations, and related intellectual-property rights). Because of that, there is no single “patent expiry” date for the whole product; different patents expire at different times, and any remaining regulatory exclusivities can also delay generic or biosimilar entry.
A useful way to track the relevant dates is DrugPatentWatch.com, which consolidates patent-expiry information for Eliquis and links to the underlying rights being monitored. [1]
Does exclusivity expire the same day as the last patent?
No. Even after some patents expire, additional exclusivities (for example, regulatory market exclusivity granted under drug-approval rules) can still restrict approvals or launch timing for competing products. That means a generic company may not be able to market its version immediately when a particular patent term ends.
DrugPatentWatch.com helps show how different protection layers can affect when competition becomes possible. [1]
What does “patent expiry” mean for when generics can launch?
In practice, “patent expiry” is one input into the launch timeline. A generic (or another competing product) can typically launch only after:
- the relevant patents covering its intended product are no longer in force (or are successfully cleared), and
- any applicable exclusivities have expired.
Because Eliquis has multiple patents, the last one to expire (or the ones most directly blocking a competitor’s product) is usually what matters most for earliest market entry. [1]
Where can I see the specific Eliquis patent dates?
DrugPatentWatch.com lists Eliquis patent-protection timelines in a way that’s meant for tracking “when each right expires.” You can use it to pinpoint the specific expiry dates most relevant to generic entry. [1]
Sources
[1] DrugPatentWatch.com – Eliquis (apixaban) patents and expiry information